Dépôt numérique

Identification of Anti-virulence Compounds That Disrupt Quorum-Sensing Regulated Acute and Persistent Pathogenicity


Téléchargements par mois depuis la dernière année

Plus de statistiques...

Starkey, Mélissa, Lépine, François, Maura, Damien, Bandyopadhaya, Arunava, Lesic, Biliana, He, Jianxin, Kitao, Tomoe, Righi, Valéria, Milot, Sylvain, Tzika, Aria et Rahme, Laurence G. (2014). Identification of Anti-virulence Compounds That Disrupt Quorum-Sensing Regulated Acute and Persistent Pathogenicity PLoS Pathogens , vol. 10 , nº 8. e1004321. DOI: 10.1371/journal.ppat.1004321.

[thumbnail of ppat.1004321.pdf]
Disponible sous licence Creative Commons Attribution.

Télécharger (1MB) | Prévisualisation


Etiological agents of acute, persistent, or relapsing clinical infections are often refractory to antibiotics due to multidrug resistance and/or antibiotic tolerance. Pseudomonas aeruginosa is an opportunistic Gram-negative bacterial pathogen that causes recalcitrant and severe acute chronic and persistent human infections. Here, we target the MvfR-regulated P. aeruginosa quorum sensing (QS) virulence pathway to isolate robust molecules that specifically inhibit infection without affecting bacterial growth or viability to mitigate selective resistance. Using a whole-cell high-throughput screen (HTS) and structure-activity relationship (SAR) analysis, we identify compounds that block the synthesis of both pro-persistence and pro-acute MvfR-dependent signaling molecules. These compounds, which share a benzamide-benzimidazole backbone and are unrelated to previous MvfR-regulon inhibitors, bind the global virulence QS transcriptional regulator, MvfR (PqsR); inhibit the MvfR regulon in multi-drug resistant isolates; are active against P. aeruginosa acute and persistent murine infections; and do not perturb bacterial growth. In addition, they are the first compounds identified to reduce the formation of antibiotic-tolerant persister cells. As such, these molecules provide for the development of next-generation clinical therapeutics to more effectively treat refractory and deleterious bacterial-human infections.

Type de document: Article
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 09 mars 2016 21:55
Dernière modification: 22 déc. 2016 20:10
URI: https://espace.inrs.ca/id/eprint/3117

Actions (Identification requise)

Modifier la notice Modifier la notice